lunedì, 4 maggio 2026

Notizie AIOM – anno XVII

FDA Approves TAS-102 for Gastric/GEJ Cancer

February 25, 2019 - The FDA has approved TAS-102 (trifluridine/tipiracil) for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, ...
Leggi tutto

Procedural update on submission of Type I variations to EMA in March, April and May 2019

February 26, 2019 - EMA is encouraging marketing authorisation holders (MAHs) intending to submit Brexit-related Type IA and Type IB variations in March 2019 to file these variations as early as possible during the month. This will enable EMA to process the submissions before ...
Leggi tutto

25 Febbraio 2019

22 febbraio 2019 – Open AIFA: l’Agenzia incontra le associazioni dei pazienti

22 Febbraio 2019

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. ...
Leggi tutto

22 Febbraio 2019

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves ...
Leggi tutto

22 Febbraio 2019

FDA Grants Pembrolizumab Priority Review for Advanced SCLC

February 20, 2019 - The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for pembrolizumab as a treatment for patients with advanced small cell lung cancer (SCLC) whose disease has progressed following ≥2 prior lines ...
Leggi tutto

22 Febbraio 2019

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer

Patients with HIV infection are at increased risk for cancer. Cancer is the leading cause of death among non–AIDS-defining illnesses in these patients. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of cancer. However, clinical trials of ICIs ...
Leggi tutto

22 Febbraio 2019

Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM

Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, firmate da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...
Leggi tutto

22 Febbraio 2019

Dal Soroptimist International Club Genova a favore delle ragazze STEM

Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: ...
Leggi tutto

22 Febbraio 2019

19 febbraio 2019 – Avviso per il conferimento dell’incarico dì livello dirigenziale non generale di direzione dell’Area Strategia ed economia del farmaco